Spyre Therapeutics
SYRE
77 hedge funds and large institutions have $137M invested in Spyre Therapeutics in 2019 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 35 increasing their positions, 9 reducing their positions, and 8 closing their positions.
289% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 9
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
8% more funds holding
Funds holding: 71 → 77 (+6)
0.04% more ownership
Funds ownership: 2.74% → 2.78% (+0.04%)
14% less capital invested
Capital invested by funds: $159M → $137M (-$21.9M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.52M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$1.96M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.38M |
| 4 |
AG
Artal Group
Luxembourg
|
+$1.17M |
| 5 |
State Street
Boston,
Massachusetts
|
+$963K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$6.25M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.45M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$2.19M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$619K |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$179K |
SYRE Hedge Fund Activity: Q2 2019 in Review
77 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q2 2019, worth a combined $137M — down 14% from $159M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new SYRE positions and 8 closed out — a net gain of 8 holders — while 35 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $2.52M. The largest seller was Jennison Associates, exiting entirely with an estimated $6.25M sold.
- 77 institutional investors held Spyre Therapeutics (SYRE) as of Q2 2019, up from 71 in Q1 2019.
- Funds reported $137M of Spyre Therapeutics stock for Q2 2019, down 14% quarter-over-quarter.
- 16 funds opened new Spyre Therapeutics positions in Q2 2019 and 8 closed out, a net change of +8 holders.
- The largest Spyre Therapeutics buyer in Q2 2019 was BlackRock, an estimated $2.52M added.
- The largest Spyre Therapeutics seller in Q2 2019 was Jennison Associates, an estimated $6.25M sold.
Based on aggregated 13F filings for Q2 2019.